Genervon is a late clinical stage biopharmaceutical company focusing on transformative, first-in-class treatments for neurodegenerative diseases and disorders.

To date, no effective therapy has been successfully developed for such conditions, and the reasons may be twofold.

First, scientists have identified many disease targets of various neurodegenerative indications that need to be modulated to affect the disease. The current paradigm of single-target drug development continues to result in clinical trial failures. Second, there is a considerable overlap of common driver pathways and targets across neurodegenerative diseases. The ability to regulate the underlying corrupted pathways and targets will be a game changer.

Taking a system biology approach, Genervon hypothesized and discovered an endogenous embryonic stage regulator of the human nervous system named Motoneuronotrophic Factor (MNTF). MNTF has been shown to specifically activate the Insulin Receptor, can differentiate murine embryonic stem cells, and promotes axonogenesis and motor neuron regeneration. 

Based on this multi-year research and drug development effort after the discovery of MNTF, Genervon has advanced GM6, a 6-amino acid active analog of MNTF, into Phase 2 clinical development. Preclinical and clinical data have shown GM6 to be safe and well-tolerated. GM6 can up and down regulate key biomarkers associated with neurodegenerative disorders and improve clinical outcomes. 

GM6 may effectively target the common pathophysiology underlying neurodegenerative conditions in which GM6 may delay neurological disease progression by up and down regulating no fewer than two dozen genes in the Axonal Transport sub-system. GM6 reduced several dozen mitochondrial gene expressions and potential mitochondrial abundance. GM6 may disrupt the mitochondrial apoptotic pathways across several disease indications. 

Genervon is planning late stage clinical trials for ALS, Parkinson's Disease, Alzheimer's Disease and Multiple Sclerosis.